Amalgamated Bank Sells 2,054 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

Amalgamated Bank lowered its holdings in shares of Shockwave Medical, Inc. (NASDAQ:SWAV) by 7.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,004 shares of the company’s stock after selling 2,054 shares during the period. Amalgamated Bank owned approximately 0.07% of Shockwave Medical worth $4,765,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Wellington Management Group LLP boosted its stake in Shockwave Medical by 33.5% in the 3rd quarter. Wellington Management Group LLP now owns 1,805,771 shares of the company’s stock worth $359,529,000 after purchasing an additional 453,048 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in shares of Shockwave Medical by 21.8% during the third quarter. Artisan Partners Limited Partnership now owns 1,398,136 shares of the company’s stock valued at $278,369,000 after buying an additional 250,352 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Shockwave Medical by 35.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 645,634 shares of the company’s stock valued at $128,546,000 after acquiring an additional 170,369 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in Shockwave Medical by 66.7% in the 3rd quarter. Canada Pension Plan Investment Board now owns 386,321 shares of the company’s stock valued at $76,917,000 after acquiring an additional 154,637 shares in the last quarter. Finally, International Assets Investment Management LLC boosted its stake in Shockwave Medical by 18,122.1% during the 4th quarter. International Assets Investment Management LLC now owns 141,586 shares of the company’s stock valued at $26,981,000 after purchasing an additional 140,809 shares during the last quarter. Institutional investors own 95.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SWAV. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $335.00 price target (up from $270.00) on shares of Shockwave Medical in a report on Monday, April 8th. Wolfe Research reiterated a “peer perform” rating on shares of Shockwave Medical in a research note on Friday, April 5th. SVB Leerink reaffirmed a “market perform” rating and issued a $335.00 target price (down previously from $361.00) on shares of Shockwave Medical in a report on Monday, April 8th. CL King reissued a “neutral” rating on shares of Shockwave Medical in a report on Monday, April 8th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $335.00 target price (up previously from $285.00) on shares of Shockwave Medical in a research report on Monday, April 8th. Ten analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $309.11.

Insiders Place Their Bets

In related news, VP Trinh Phung sold 599 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $259.24, for a total transaction of $155,284.76. Following the sale, the vice president now owns 31,031 shares in the company, valued at approximately $8,044,476.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Douglas Evan Godshall sold 10,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $231.56, for a total value of $2,315,600.00. Following the sale, the chief executive officer now directly owns 162,762 shares in the company, valued at $37,689,168.72. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Trinh Phung sold 599 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $259.24, for a total value of $155,284.76. Following the transaction, the vice president now owns 31,031 shares of the company’s stock, valued at approximately $8,044,476.44. The disclosure for this sale can be found here. Insiders have sold 83,120 shares of company stock valued at $21,319,021 over the last ninety days. 3.40% of the stock is owned by insiders.

Shockwave Medical Stock Up 0.1 %

Shares of SWAV opened at $330.49 on Wednesday. The business’s 50 day simple moving average is $304.38 and its 200-day simple moving average is $240.04. Shockwave Medical, Inc. has a 1 year low of $157.00 and a 1 year high of $331.58. The company has a debt-to-equity ratio of 1.09, a current ratio of 11.76 and a quick ratio of 10.73. The stock has a market capitalization of $12.40 billion, a price-to-earnings ratio of 85.40, a price-to-earnings-growth ratio of 2.46 and a beta of 0.88.

Shockwave Medical (NASDAQ:SWAV) last released its quarterly earnings data on Monday, May 6th. The company reported $1.44 EPS for the quarter, beating the consensus estimate of $0.99 by $0.45. The business had revenue of $218.80 million during the quarter, compared to analyst estimates of $207.69 million. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. Shockwave Medical’s quarterly revenue was up 35.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.03 earnings per share. As a group, equities analysts expect that Shockwave Medical, Inc. will post 4.94 earnings per share for the current fiscal year.

Shockwave Medical Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.